Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Jan 12, 2010

Premium

PBL InterferonSource last week launched its Quansys Q-Plex cytokine multiplex ELISA arrays, high-throughput interferon detection kits that the firm believes will enable drug discovery and clinical research efforts in the treatment of infectious diseases and autoimmunity.

Developed by Quansys Biosciences, the quantitative enzyme-linked immunosorbant assay-based tests contain up to 16 distinct capture antibodies in each well of a 96-well plate. Using the system, up to 84 different samples can be assayed for 16 cytokines in less than two and a half hours, PBL claimed. Current Q-Plex products include six human and four mouse cytokine arrays that are compatible with serum, plasma, cell culture supernatant, homogenates, lysates, nasal lavage, tears, and urine

According to PBL, the Q-Plex kits allow users to assess cytokine profiles at various points throughout the course of disease; correlate cytokine profile alterations with patient responses to therapies; and determine drugs' off-target effects. Later this year, PBL said it will launch human interferon-based multiplex ELISA arrays that can quantify the levels of Type I, II and III human interferons


GeneGo has included access to Sigma-Aldrich life science and chemistry products in its MetaCore 6.0, MetaDrug, and Eureka products. GeneGo said that customers can now retrieve comprehensive information on drugs and compounds and make one-click purchases from one centralized location.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.